BRPI0508266A - escitalopram oxalate crystalline particles, solid single dosage form, and methods for the manufacture of escitalopram oxalate crystalline particles and for reducing the amount of hydroxyl containing impurities in citalopram, escitalopram or a non-racemic mixture of r- and s -citalopram - Google Patents

escitalopram oxalate crystalline particles, solid single dosage form, and methods for the manufacture of escitalopram oxalate crystalline particles and for reducing the amount of hydroxyl containing impurities in citalopram, escitalopram or a non-racemic mixture of r- and s -citalopram

Info

Publication number
BRPI0508266A
BRPI0508266A BRPI0508266-8A BRPI0508266A BRPI0508266A BR PI0508266 A BRPI0508266 A BR PI0508266A BR PI0508266 A BRPI0508266 A BR PI0508266A BR PI0508266 A BRPI0508266 A BR PI0508266A
Authority
BR
Brazil
Prior art keywords
escitalopram
crystalline particles
citalopram
escitalopram oxalate
oxalate crystalline
Prior art date
Application number
BRPI0508266-8A
Other languages
Portuguese (pt)
Inventor
Kim Bojstrup Jensen
Rikke Eva Humble
Ken Liljegren
Troels Volsgaard Christensen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34921251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0508266(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of BRPI0508266A publication Critical patent/BRPI0508266A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Abstract

PARTìCULAS CRISTALINAS DE OXALATO DE ESCITALOPRAM, FORMA DE DOSAGEM úNICA SóLIDA, E, MéTODOS PARA A FABRICAçãO DE PARTìCULAS DE OXALATO DE ESCITALOPRAM E PARA REDUZIR A QUANTIDADE DE HIDROXILA QUE CONTéM IMPUREZAS NO CITALOPRAM, ESCITALOPRAM OU UMA MISTURA NãO RACêMICA DE R- ES-CITALOPRAM A presente invenção divulga partículas cristalinas de oxalato de escitalopram que têm uma distribuição de tamanho de partícula ampla ou que compreende pelo menos 0,01 % (p/p) de Z-4-(4-dimetilamino-1-(4-fluoro-fenil)-but-1-enil)-3-hidroximetil-benzoni trila, as ditas partículas sendo adequadas para o uso na compressão direta. Além disso, a invenção divulga uma nova forma de dosagem única, farmacêutica que contém tais partículas cristalinas de oxalato de escitalopram bem como métodos para a fabricação de tais partículas cristalinas de oxalato de escitalopram. Finalmente, a invenção fornece um método para a redução da quantidade de hidroxila que contém impurezas em uma solução de citalopram ou escitalopram.Crystalline Particles Of Scithalop Oxalate, Form Of Solid Only Dosage, And Methods For The Manufacture Of Scithalopra Oxide And To Reduce The Amount Of HYDROXYAL SCRIPTURE IN THE SCPALOPHRAM The present invention discloses escitalopram oxalate crystalline particles having a broad particle size distribution or comprising at least 0.01% (w / w) of Z-4- (4-dimethylamino-1- (4-fluoro). phenyl) -but-1-enyl) -3-hydroxymethylbenzonitrile, said particles being suitable for use in direct compression. In addition, the invention discloses a novel single pharmaceutical dosage form containing such escitalopram oxalate crystalline particles as well as methods for the manufacture of such escitalopram oxalate crystalline particles. Finally, the invention provides a method for reducing the amount of hydroxyl containing impurities in a citalopram or escitalopram solution.

BRPI0508266-8A 2004-03-05 2005-02-21 escitalopram oxalate crystalline particles, solid single dosage form, and methods for the manufacture of escitalopram oxalate crystalline particles and for reducing the amount of hydroxyl containing impurities in citalopram, escitalopram or a non-racemic mixture of r- and s -citalopram BRPI0508266A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55090904P 2004-03-05 2004-03-05
DKPA200400382 2004-03-05
PCT/DK2005/000115 WO2005084643A1 (en) 2004-03-05 2005-02-21 Crystalline composition containing escitalopram oxalate

Publications (1)

Publication Number Publication Date
BRPI0508266A true BRPI0508266A (en) 2007-07-31

Family

ID=34921251

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508266-8A BRPI0508266A (en) 2004-03-05 2005-02-21 escitalopram oxalate crystalline particles, solid single dosage form, and methods for the manufacture of escitalopram oxalate crystalline particles and for reducing the amount of hydroxyl containing impurities in citalopram, escitalopram or a non-racemic mixture of r- and s -citalopram

Country Status (9)

Country Link
EP (1) EP1732514A1 (en)
JP (1) JP2007526262A (en)
AU (1) AU2005218713B2 (en)
BR (1) BRPI0508266A (en)
CA (1) CA2558198A1 (en)
EA (1) EA200601641A1 (en)
NO (1) NO20064499L (en)
NZ (1) NZ549100A (en)
WO (1) WO2005084643A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI347942B (en) * 2005-06-22 2011-09-01 Lundbeck & Co As H Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
CA2672925A1 (en) 2006-10-20 2008-04-24 Ratiopharm Gmbh Escitalopram and solid pharmaceutical composition comprising the same
EP2116231A1 (en) * 2008-05-07 2009-11-11 Hexal Ag Granulate comprising escitalopram oxalate
JP2018016569A (en) * 2016-07-26 2018-02-01 株式会社トクヤマ Production method of (1s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile oxalate
JP6554245B1 (en) * 2019-01-31 2019-07-31 第一工業製薬株式会社 2,2'-bis (2-hydroxyethoxy) -1,1'-binaphthalene powder

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
CA2445843A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
AR034612A1 (en) * 2001-06-25 2004-03-03 Lundbeck & Co As H PROCESS FOR THE PREPARATION OF RACEMIC CITALOPRAM AND / OR OF THE S- OR R-CITALOPRAM THROUGH THE SEPARATION OF A MIXING OF R- AND S-CITALOPRAM
UA79930C2 (en) * 2001-07-31 2007-08-10 Lundbeck & Co As H Crystalline composition containing escitalopram
TWI306846B (en) * 2002-08-12 2009-03-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
WO2004056791A1 (en) * 2002-12-23 2004-07-08 H. Lundbeck A/S Escitalopram hydrobromide and a method for the preparation thereof
TR200504022T1 (en) * 2003-03-24 2006-08-21 Hetero Drugs Limited New liquid crystal forms of (S) -sitalopram oxalate.

Also Published As

Publication number Publication date
JP2007526262A (en) 2007-09-13
WO2005084643A1 (en) 2005-09-15
NZ549100A (en) 2010-02-26
CA2558198A1 (en) 2005-09-15
NO20064499L (en) 2006-12-04
AU2005218713B2 (en) 2009-11-19
EA200601641A1 (en) 2006-12-29
AU2005218713A1 (en) 2005-09-15
EP1732514A1 (en) 2006-12-20

Similar Documents

Publication Publication Date Title
BRPI0508266A (en) escitalopram oxalate crystalline particles, solid single dosage form, and methods for the manufacture of escitalopram oxalate crystalline particles and for reducing the amount of hydroxyl containing impurities in citalopram, escitalopram or a non-racemic mixture of r- and s -citalopram
BRPI0705721A (en) encapsulation of bulky fragrance molecules
BR9914932A (en) Process for the manufacture of an isotretinoin composition, micronized isotretinoin composition, unit dosage form for enteral administration and pharmaceutical composition in unit form
BR0214431A (en) Stable ginger extract preparation, process for producing it, galenic preparation, and use of a stabilized ginger extract preparation and a galenic preparation
RS8304A (en) Crystalline composition containing escitalopram
BRPI0502442A (en) opaque dental ceramics, process for preparation as well as its application
BRPI0417672A (en) processes for producing storage stable virus compositions, virus and immunogenic compositions
BR9806895A (en) New formulation; showing volumetric density, when spilled, from 0.20 to 038 g / ml, comprising formoterol
AR061093A1 (en) CALCIUM COMPOSITIONS
CN105461342A (en) An attapulgite ceramic filter material for water treatment
WO2005094385A3 (en) Non-toxic disinfectant containing a isopropyl alcohol and sesame oil composition with lemon oil and menthol
CN105561956A (en) Automobile exhaust purifying agent
CL2004000979A1 (en) NONAPEPTIDES CLOSED LYSOBACITINE TYPE, COMPOSITION THAT CONTAINS THEM PREPARATION METHOD, USED AS BACTERICIDE.
UY27727A1 (en) NEW PHARMACEUTICAL COMPOSITION-
KR850700211A (en) Manufacturing method of solid perfume
BR0318411A (en) non-toxic mucous disinfectant containing isopropyl alcohol, sesame oil, aloe and lemon oil
BR0311475A (en) Elastomeric compounds having a high filler content, method for their production, and use of microsilica
ES2156147T3 (en) COMPOSITIONS TO ELIMINATE CAL INCRUSTATIONS.
BRPI0407519A (en) benzofuran derivatives
KR840003225A (en) Cement inflator
BR0011261A (en) Oral composition comprising perlite, and use of perlite
MX9307203A (en) STEROIDAL COMPOUNDS OF ACIL-3-CARBOXI-3,5-DIENO-17Ó AND 17ß-SUBSTITUTED.
KR970065471A (en) Alumina Sintered Body and Manufacturing Method Thereof
ES2162549B1 (en) "PROCEDURE FOR THE PRODUCTION OF SYNTHETIC DOLOMITE".
BR0012043A (en) Composition of hair treatment

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 9A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.